Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240285 | 0.90 | ADRB2 (0.45) | MAOAMAOBLMNAMEN1KMT2A | |
| SCHEMBL4231930 | 0.90 | MEN1 (0.41) | MAOAMAOBNAAALMNAMEN1 | |
| SCHEMBL4239009 | 0.88 | MAOA (0.44) | MAOAMAOBLMNAMEN1KMT2A | |
| SCHEMBL4233984 | 0.86 | KDR (0.38) | MAOAMAOBLMNAMAPT | |
| SCHEMBL4233515 | 0.85 | HTR4 (0.43) | MAOAMAOBMEN1KMT2AADRB2 | |
| SCHEMBL4233458 | 0.85 | ADRB2 (0.46) | MAOAMAOBLMNAMEN1KMT2A | |
| SCHEMBL4227016 | 0.83 | MAOA (0.42) | MAOAMAOBLMNAMEN1KMT2A | |
| SCHEMBL4229335 | 0.78 | KMT2A (0.37) | MAOAMAOBMEN1KMT2AADRB2 | |
| SCHEMBL4226703 | 0.75 | SMN1; SMN2 (0.39) | MEN1KMT2AMAPT | |
| SCHEMBL4238055 | 0.74 | HRH3 (0.58) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MAOA 219/4885MAOB 169/4885NAAA 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.